Mechanisms of Exercise-induced Hypoalgesia

April 22, 2025 updated by: Université Catholique de Louvain

Disentangling Peripheral and Central Mechanisms of Exercise-induced Hypoalgesia in Healthy Adults Males.

This project aims to clarify the mechanisms underpinning the acute analgesic effect of exercise in healthy humans-a phenomenon called "Exercise-induced hypoalgesia" (EIH). This study will characterize, using a within-subject cross-over design, the effects of a single session of aerobic exercise vs. a control condition on the sensitivity to stimuli preferentially activating mechano vs. heat-sensitive nociceptors of the skin vs. muscle, within vs. outside exercising body parts. The investigators hypothesize (1) that EIH will be greater in the exercise session compared to the control session, (2) that EIH will be greater at the local site compared to the remote site if local changes in nociceptive sensitivity contribute to EIH, and (3) that exercise will preferentially affect blunt pressure-induced pain if EIH involves specific changes in sensitivity of muscle nociceptors.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Brussels, Belgium, 1200
        • Institute of Neuroscience, UCLouvain

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Males aged between 18 and 30 years
  • Lack of risks for physical exercise assessed using the Physical Activity Readiness Questionnaire (PAR-Q)
  • Ability to provide written informed consent
  • Fluency in French
  • BMI between 17 and 30

Exclusion Criteria:

  • Regular tobacco use
  • Not willing or able to abstain from alcohol, recreational drugs, coffee, or tea from 24 hours prior to each experimental session.
  • Not willing or able to restrain from physical activity > 24h prior to each experimental session, and to be in a fasted state on the day of each experimental session.
  • Any neurological, cardio-vascular, respiratory, inflammatory, endocrine, psychiatric, oncological, rheumatological conditions. Such condition could put the participants at risk during maximal exercise testing and/or interfere with pain assessment.
  • Presence of any medical devices (e.g., cardiac pacemaker) implants or prothesis unless it is beyond discussion that these will not put the subject's safety during the study at risk and will not interfere with the results of the study.
  • Any chronic pain condition or recent history thereof (i.e. within the preceeding 2 years).
  • Wounds or skin alteration on testing sites.
  • Impaired hearing. This would affect ability to detect the control auditory stimuli.
  • Surgery < 12 months
  • Any drug intake in the past 2 weeks including antibiotics, herbal medicines and other remedies except the following drugs that will be allowed up to 48 hours prior to the experiments: oral paracetamol or ibuprofen for a self-limiting condition (e.g. toothache, bruise). Oral antihistaminics and nasal aerosol and topical treatments for seasonal allergy up to 1 week before the experimental session.
  • Any physical activity contraindication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental condition
Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
Sham Comparator: Control condition
The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase >25% from baseline
The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase >25% from baseline.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pressure pain threshold
Time Frame: Throughout the entire study, approximately during 6 months
The investigators will use blunt pressure to preferentially activate the mechano-sensitive deep-tissue nociceptors. The stimuli will be delivered with a manual digital algometer with a contact surface area of 1cm2 (FPIX; Wagner Instruments, Greenwich, USA) connected to a laptop computer through a USB-serial port. A bespoke Matlab (The Mathworks, USA, mathworks.com) script will provide visual feedback of the force application rate to the examinator. The participants will be asked to report the first onset of pain by pressing on a keyboard key. The procedure is safe, and there are no side effects to the stimulation. This outcome will measured before and after each of the condition of the study (experimental exercise vs. control exercise)-relative and absolute change will then be computed.
Throughout the entire study, approximately during 6 months
Change in cold detection threshold and heat pain threshold
Time Frame: Throughout the entire study, approximately during 6 months
The investigators will apply thermal stimuli to the skin to activate selectively heat-sensitive Aδ- and C-cutaneous fibre afferents. The thermal stimuli will be produced by a contact thermode based on Peltier elements (TCS-2; QST.lab, Strasbourg). The cold detection threshold (CDT) will be estimated by asking participants to press a button as soon as a decrease in skin temperature is noticed. The heat pain threshold (HPT) will be estimated by asking participants to press a button as soon as the increase in skin temperature becomes painful. This device is safe and routinely used for diagnostic purposes. The thermal stimulators will be used, in accordance with safety guidelines. If requested by the participant, the stimulation procedure can be stopped at any time, with no after effect. This outcome will measured before and after each of the condition of the study (experimental exercise vs. control exercise)-relative and absolute change will then be computed.
Throughout the entire study, approximately during 6 months
Change in rating of mechanical activation of cutaneous nociceptive afferents
Time Frame: Throughout the entire study, approximately during 6 months
The investigators will use calibrated mechanical pinprick stimulators with a small surface probe to selectively activate the skin mechanosensitive nociceptors (The PinPrick; MRC Systems GmbH, Heidelberg, Germany). Upon each stimulation, the participants will be asked to provide a rating of pain on a 100mm Visual Analogue Scale (VAS) anchored from "No sensation" to "Worst pain imaginable" with a mark in the middle denoting the transition from unpainful to painful sensations. To avoid sensitization/habituation of the skin, the location of the stimulus will be slightly changed for each stimulation. The sensation perceived by pinprick stimulation are most often described as pricking and sometimes like a touch sensation. The procedure is safe, and there are no side effects to the stimulation. This outcome will measured before and after each of the condition of the study (experimental exercise vs. control exercise)-relative and absolute change will then be computed.
Throughout the entire study, approximately during 6 months
Change in auditory detection threshold
Time Frame: Throughout the entire study, approximately during 6 months
The auditory stimulation will consist in a progressively increasing tone delivered at a comfortable hearing level using a pair of commercially available headphones. The participants will report the perception of the sound by pressing on a keyboard key. This outcome will measured before and after each of the condition of the study (experimental exercise vs. control exercise)-relative and absolute change will then be computed.
Throughout the entire study, approximately during 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: André Mouraux, Full professor, MD, Institute of Neuroscience, UCLouvain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 26, 2023

Primary Completion (Actual)

October 1, 2023

Study Completion (Actual)

October 1, 2023

Study Registration Dates

First Submitted

July 6, 2023

First Submitted That Met QC Criteria

July 17, 2023

First Posted (Actual)

July 27, 2023

Study Record Updates

Last Update Posted (Actual)

April 25, 2025

Last Update Submitted That Met QC Criteria

April 22, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • EIH

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe